This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer. Patients are randomized into study group and control group. In study group, patients accept long-acting G-CSF 48 hours from the chemotherapy. While the control group accept regular treatment rather than long-acting G-CSF. The primary end is the incidence of FN in every course of chemotherapy. The secondary ends include: the incidences of myelosuppression, doses of G-CSF and its expenses, visits to outpatient and emergency clinics, adverse events related to G-CSF.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
556
A 6 mg of polyethylene glycol granulocyte colony stimulating factor will be given to patients of study group
Short-term granulocyte colony stimulating factor will be given to all patients according to the severity of myelosuppression
Lei Li
Beijing, Beijing Municipality, China
RECRUITINGfebrile neutropenia
the incidence of febrile neutropenia happened during each course of chemotherapy
Time frame: One year
myelosuppression
the incidence of the incidence of febrile neutropenia happened during each course of chemotherapy happened during each course of chemotherapy
Time frame: One year
doses of granulocyte colony stimulating factor
total doses of all granulocyte colony stimulating factor
Time frame: One year
expenses of granulocyte colony stimulating factor
total expenses of all granulocyte colony stimulating factor
Time frame: One year
visits to the hospital
visits to outpatient and emergency clinics
Time frame: One years
adverse events
adverse events related to G-CSF according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03
Time frame: One year
progression-free survival
progression-free survival after the primary treatment of ovarian cancer
Time frame: Five years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.